Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use of Levosimendan as Treatment of Aneurysmal Subarachnoid Hemorrhage
2021-001702-30Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of levosimendan in subarachnoid hemorrhage (SAH), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Cerebral arterial vasospasm within 14 days. Started Nov 2021; status: active.
02
Drugs
levosimendan
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2021-001702-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001702-30.